Analyst Price Targets — AGEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 11, 2026 10:08 am | — | H.C. Wainwright | $25.00 | $7.00 | TheFly | Agenus price target lowered to $25 from $30 at H.C. Wainwright |
| November 29, 2024 11:34 am | Emily Bodnar | H.C. Wainwright | $7.00 | $3.57 | StreetInsider | H.C. Wainwright Reiterates Neutral Rating on Agenus Inc. (AGEN) |
| July 19, 2024 8:55 am | Biren Amin | Jefferies | $7.00 | $5.99 | StreetInsider | Jefferies Downgrades Agenus Inc. (AGEN) to Hold |
| July 19, 2024 4:59 am | Colleen Kusy | Robert W. Baird | $8.00 | $7.30 | TheFly | Agenus downgraded to Neutral from Outperform at Baird |
| July 18, 2024 12:33 pm | Emily Bodnar | H.C. Wainwright | $9.00 | $7.98 | TheFly | Agenus downgraded to Neutral from Buy at H.C. Wainwright |
| July 1, 2024 6:42 am | Emily Bodnar | H.C. Wainwright | $20.00 | $8.38 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Agenus Inc. (AGEN) |
Latest News for AGEN
Agenus Inc. (NASDAQ: AGEN - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $4.36 and traded as high as $8.00. Agenus shares last traded at $7.99, with a volume of 676,249 shares. Analyst Upgrades and Downgrades AGEN has been the
[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Ar
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen, Head of Corporate Development and Investor Relations, will participate in fireside chats and one-on-one investor meetings at two upcoming investor conferences in September. Cantor Global Healthcare Conference 2026…
[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from t
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), a multifunctional Fc-enhanced anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in 123 heavily pre-treated patients with microsatellite-stable (MSS)…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AGEN.
U.S. House Trading
No House trades found for AGEN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.